On Monday, Shares of General Mills, Inc. (NYSE:GIS), added 0.26% and closed at $61.20 in the last trading session. The last trading range of the stock ranges between $60.66 and $61.47. General Mills (GIS) recently declared the election of Alicia S. Boler Davis to its board of directors.
Boler Davis presently serves as executive vice president, Global Manufacturing at General Motors, where she leads about 180,000 employees in more than 30 countries. She is a member of the GM Executive Leadership Team, the Opel Supervisory Board and the GM Korea Board of Directors.
“Alicia brings to our board a strong technical background in manufacturing, engineering, and quality, coupled with a passion for putting the consumer first to drive results in a highly competitive industry,” said Ken Powell, General Mills Chairman and CEO. “Her insights and experience will be invaluable as we continue to expand the impact of our global Consumer First strategy and deliver sustainable, long-term growth and returns for General Mills shareholders.”
Eli Lilly and Co (NYSE:LLY), dropped -0.84% and closed at $77.02 in the last trading session. The last trading range of the stock ranges between $76.69 and $78.24. The company’s Market capitalization is $84.30 Billion with the total Outstanding Shares of 1.10 Billion. Eli Lilly and Company (LLY) and Incyte Corporation (INCY) recently declared that in two phase 3 trials, RA-BEAM and RA-BUILD, patients with rheumatoid arthritis (RA) treated with baricitinib practiced noteworthyimprovements in patient-stated outcomes, counting joint pain, severity of morning joint stiffness and tiredness, contrast to placebo and adalimumab (Humira®)*. These findings were presented recently at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Washington DC, November 11-16, 2016.
“This analysis looked at important aspects of rheumatoid arthritis such as the pain, morning joint stiffness and tiredness that are common and debilitating symptoms for patients,” said Terence Rooney, M.D., Lilly’s senior medical director for baricitinib. “Our study results show that treatment with baricitinib rapidly led to significantly greater symptom improvement contrast to adalimumab and placebo. The results are very encouraging, and further support baricitinib as a potential oral treatment for those living with RA.”
Fastenal Company (NASDAQ:FAST), gained 1.85% and closed at $45.10 in the last trading session. The last trading range of the stock ranges between $44.39 and $45.43.Company stock’s 52-week range is $35.10 – $49.99 Fastenal Company, together with its auxiliaries, engages in the wholesale distribution of industrial and construction supplies in the United States, Canada, and internationally. It offers fasteners, and other industrial and construction supplies mainly under the Fastenal name. The companys fastener products include threaded fasteners, such as bolts, nuts, screws, studs, and related washers, which are used in manufactured products and building projects, in addition to in the maintenance and repair of machines and structures. It also offers miscellaneous supplies and hardware, counting various pins and machinery keys, concrete anchors, metal framing systems, wire ropes, strut products, rivets, and related accessories. The company serves the manufacturing market comprising original equipment manufacturers, maintenance, repair, and operations; and non-residential construction market, which include general, electrical, plumbing, sheet metal, and road contractors. It also serves farmers, truckers, railroads, mining companies, schools, and retail trades; and oil exploration, production, and refinement companies, in addition to federal, state, and local governmental entities.